Summary

Description

The Antibody Drug Conjugates Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise of Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) are revolutionizing cancer therapy by merging the precision of targeted treatment with the potency of cytotoxic agents. These innovative therapies deliver powerful payloads, such as DNA-damaging agents or microtubule inhibitors, directly to cancer cells, reducing off-target effects and systemic toxicity. This advancement has allowed ADCs to expand their efficacy from treating haematological cancers to solid tumours, addressing complex malignancies like ovarian and lung cancers.

Additionally, over 90 ADC candidates in clinical trials, as of 2023, signal a robust and promising pipeline. Breakthroughs such as bispecific ADCs and combination therapies are paving the way for higher success rates and expanded applications. Startups and established pharmaceutical players are collaborating to push these boundaries further, with companies like AstraZeneca and Daiichi Sankyo achieving global milestones. For instance, on 19th October 2023, Daiichi Sankyo and Merck entered a global agreement to jointly develop and potentially commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). This collaboration will cover worldwide development and commercialization, excluding Japan, where Daiichi Sankyo will retain exclusive rights. Additionally, Daiichi Sankyo will handle all manufacturing and supply operations. While production challenges and cost concerns remain, the future of ADCs appears bright, driven by continuous innovation and strategic investments.

Antibody-Drug Conjugates: Pioneering the Future of Precision Cancer Therapy

The advent of Antibody-Drug Conjugates (ADCs) marks a significant milestone in the evolution of precision cancer treatment. By targeting specific cancer antigens and delivering payloads with pinpoint accuracy, ADCs are reducing side effects while enhancing therapeutic outcomes. This precision has been amplified by advancements in molecular diagnostics, such as biomarker identification, enabling treatments to be tailored to individual patient needs.

However, the journey is not without hurdle, the ADC production demands specialized technologies and facilities, driving up costs and complicating reimbursement structures. For instance, disparities in coverage policies, even in developed regions like the UK, hinder patient access to these life-saving therapies. Yet, emerging economies like China and India show potential for growth as healthcare infrastructures evolve. Industry leaders, including Pfizer, F. Hoffmann-La Roche, Astellas Pharma Inc., GSK, and AstraZeneca among others are making strides to lower production costs and increase access. By fostering global collaborations and embracing innovation, ADCs are set to define the future of cancer therapy.

What Questions Should You Ask before Buying a Market Research Report?

• How is the antibody drug conjugates market evolving?
• What is driving and restraining the antibody drug conjugates market?
• How will each antibody drug conjugates submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each antibody drug conjugates submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading antibody drug conjugates markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the antibody drug conjugates projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2035? What are the implications of
  antibody drug conjugates projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the antibody drug conjugates market?
• Where is the antibody drug conjugates market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the antibody drug conjugates market today, and over the next 10 years:

• Our 342-page report provides 126 tables, 185 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2035 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

Payload Type

• MMAE
• DM4
• Camptothecin
• DM1
• MMAF
• Other Payload Type

Linker Type

• Cleavable Linkers
• Non-Cleavable Linkers

Target Antigen

• CD30
• HER2
• CD22
• CD33
• Other Target Antigens

Applications

• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Other Applications

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles for some of the leading companies in the Antibody Drug Conjugates Market, 2025 to 2035, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• AstraZeneca
• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company, Limited
• GSK plc
• ADC Therapeutics SA
• Synaffix BV
• Byondis
• AbbVie Inc.
• RemeGen
• Oxford BioTherapeutics
• Mersana Therapeutics
• WuXi AppTec
• Genmab A/S
• Regeneron Pharmaceuticals Inc.

Overall world revenue for Antibody Drug Conjugates Market, 2025 to 2035 in terms of value the market will surpass US$16.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Antibody Drug Conjugates Market, 2025 to 2035 report help you?

In summary, our 340+ page report provides you with the following knowledge:

• Revenue forecasts to 2035 for Antibody Drug Conjugates Market 2025 to 2035, with forecasts for Payload Type, Linker Type, Target Antigen, and Applications, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 21 key national markets – See forecasts for the Antibody Drug Conjugates Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 18 of the major companies involved in the Antibody Drug Conjugates Market, 2025 to 2035.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antibody Drug Conjugates Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Growing Burden of Cancer
3.3.1.2 Increasing Breast Cancer Cases Driving Demand for Antibody-Drug Conjugates
3.3.1.3 Presence of Strong Emerging Pipeline Drugs
3.3.1.4 Increasing R&D Activities for the Development of Novel Therapeutics
3.3.2 Market Restraining Factors
3.3.2.1 Complexities in Manufacturing
3.3.2.2 Co-ordination Between Various Biopharmaceutical and CDMOs
3.3.2.3 Antibody and Linker-Related Cytotoxin and Formulation Challenges
3.3.2.4 Adverse Effects of Antibody-Drug Conjugates
3.3.3 Market Opportunities
3.3.3.1 Adoption of Combination Therapies
3.3.3.2 Advancements in Antibody-Drug Conjugates (ADCs)
3.3.3.3 Expanding Industry Investments and Collaborations in ADC Development
3.4 SWOT Analysis
3.5 Regulatory Framework
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Competitive Rivalry
3.6.4 Threat of Substitutes
3.6.5 Threat of New Entrants
3.7 PEST
3.7.1 Political
3.7.2 Economical
3.7.3 Social
3.7.4 Technological
3.8 Current R&D and Clinical Status of Antibody Drug Conjugates
3.8.1 Antibody Drug Considerations
3.8.2 Drug to Antibody Ration (DAR)
3.8.3 Bystander Effect and Linker Design
3.8.4 Future Clinical Differentiation
3.9 Key Medical Affairs Considerations for ADCs
3.9.1 Precision in Indication and Timing
3.9.2 Combination Partners and Customisation
3.9.3 Balancing Dose and Toxicity
3.9.4 Patient-Centred Decision Making
3.10 Commercial Challenges
3.10.1 Physician Variability and Market Variability
3.10.2 Reposition Value Narratives
3.10.3 Reimbursement and Cost Considerations
3.11 Pharma is Expecting a Second Wave of ADC Launches
3.12 Approved ADCs

4 Antibody Drug Conjugates Market Analysis by Payload Type
4.1 Key Findings
4.2 Payload Type Segment: Market Attractiveness Index
4.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
4.4 MMAE
4.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
4.4.2 Market Share by Region, 2025 & 2035 (%)
4.5 DM4
4.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
4.5.2 Market Share by Region, 2025 & 2035 (%)
4.6 Camptothecin
4.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
4.6.2 Market Share by Region, 2025 & 2035 (%)
4.7 DM1
4.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
4.7.2 Market Share by Region, 2025 & 2035 (%)
4.8 MMAF
4.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
4.8.2 Market Share by Region, 2025 & 2035 (%)
4.9 Other Payload Type
4.9.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
4.9.2 Market Share by Region, 2025 & 2035 (%)

5 Antibody Drug Conjugates Market Analysis by Linker Type
5.1 Key Findings
5.2 Linker Type Segment: Market Attractiveness Index
5.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
5.4 Cleavable Linkers
5.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
5.4.2 Market Share by Region, 2025 & 2035 (%)
5.5 Non-Cleavable Linkers
5.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
5.5.2 Market Share by Region, 2025 & 2035 (%)

6 Antibody Drug Conjugates Market Analysis by Target Antigen
6.1 Key Findings
6.2 Target Antigen Segment: Market Attractiveness Index
6.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
6.4 CD30
6.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
6.4.2 Market Share by Region, 2025 & 2035 (%)
6.5 HER2
6.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
6.5.2 Market Share by Region, 2025 & 2035 (%)
6.6 CD22
6.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
6.6.2 Market Share by Region, 2025 & 2035 (%)
6.7 CD33
6.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
6.7.2 Market Share by Region, 2025 & 2035 (%)
6.8 Other Target Antigens
6.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
6.8.2 Market Share by Region, 2025 & 2035 (%)

7 Antibody Drug Conjugates Market Analysis by Applications
7.1 Key Findings
7.2 Applications Segment: Market Attractiveness Index
7.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
7.4 Blood Cancer
7.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
7.4.2 Market Share by Region, 2025 & 2035 (%)
7.5 Breast Cancer
7.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
7.5.2 Market Share by Region, 2025 & 2035 (%)
7.6 Ovarian Cancer
7.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
7.6.2 Market Share by Region, 2025 & 2035 (%)
7.7 Lung Cancer
7.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
7.7.2 Market Share by Region, 2025 & 2035 (%)
7.8 Other Applications
7.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
7.8.2 Market Share by Region, 2025 & 2035 (%)

8 Antibody Drug Conjugates Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Antibody Drug Conjugates Market Analysis
9.1 Key Findings
9.2 North America Antibody Drug Conjugates Market Attractiveness Index
9.3 North America Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
9.4 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
9.5 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
9.6 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
9.7 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
9.8 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
9.9 U.S. Antibody Drug Conjugates Market Analysis
9.10 Canada Antibody Drug Conjugates Market Analysis

10 Europe Antibody Drug Conjugates Market Analysis
10.1 Key Findings
10.2 Europe Antibody Drug Conjugates Market Attractiveness Index
10.3 Europe Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
10.4 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Country
10.5 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
10.6 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
10.7 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
10.8 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
10.9 Germany Antibody Drug Conjugates Market Analysis
10.10 UK Antibody Drug Conjugates Market Analysis
10.11 France Antibody Drug Conjugates Market Analysis
10.12 Italy Antibody Drug Conjugates Market Analysis
10.13 Spain Antibody Drug Conjugates Market Analysis
10.14 Russia Antibody Drug Conjugates Market Analysis
10.15 Rest of Europe Antibody Drug Conjugates Market Analysis

11 Asia Pacific Antibody Drug Conjugates Market Analysis
11.1 Key Findings
11.2 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
11.3 Asia Pacific Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
11.4 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Country
11.5 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
11.6 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
11.7 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
11.8 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
11.9 Japan Antibody Drug Conjugates Market Analysis
11.10 China Antibody Drug Conjugates Market Analysis
11.11 India Antibody Drug Conjugates Market Analysis
11.12 Australia Antibody Drug Conjugates Market Analysis
11.13 South Korea Antibody Drug Conjugates Market Analysis
11.14 South-East Asia Antibody Drug Conjugates Market Analysis
11.15 Rest of Asia Pacific Antibody Drug Conjugates Market Analysis

12 Latin America Antibody Drug Conjugates Market Analysis
12.1 Key Findings
12.2 Latin America Antibody Drug Conjugates Market Attractiveness Index
12.3 Latin America Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
12.4 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
12.5 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
12.6 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
12.7 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
12.8 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
12.9 Brazil Antibody Drug Conjugates Market Analysis
12.10 Mexico Antibody Drug Conjugates Market Analysis
12.11 Argentina Antibody Drug Conjugates Market Analysis
12.12 Colombia Antibody Drug Conjugates Market Analysis
12.13 Rest of Latin America Antibody Drug Conjugates Market Analysis

13 MEA Antibody Drug Conjugates Market Analysis
13.1 Key Findings
13.2 MEA Antibody Drug Conjugates Market Attractiveness Index
13.3 MEA Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
13.4 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Country
13.5 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
13.6 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
13.7 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
13.8 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
13.9 GCC Antibody Drug Conjugates Market Analysis
13.10 South Africa Antibody Drug Conjugates Market Analysis
13.11 Rest of MEA Antibody Drug Conjugates Market Analysis

14 Company Profiles
14.1 Competitive Landscape
14.1.1 Strategic Collaborations in the ADC Space to Redefine Cancer Treatment
14.1.2 Pioneering Innovations Redefining Cancer Care and Broader Health Solutions
14.2 Takeda Pharmaceutical Company Limited
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2018-2023
14.2.3.2 R&D, 2018-2023
14.2.3.3 Regional Market Shares, 2023
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 F. Hoffmann-La Roche Ltd.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2018-2023
14.3.3.2 R&D, 2018-2023
14.3.3.3 Business Segment Market Shares, 2023
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Pfizer Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2018-2023
14.4.3.2 R&D, 2018-2023
14.4.3.3 Regional Market Shares, 2023
14.4.3.4 Business Segment Market Shares, 2023
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 AstraZeneca
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2018-2023
14.5.3.2 R&D, 2018-2023
14.5.3.3 Regional Market Shares, 2023
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Gilead Sciences, Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2018-2023
14.6.3.2 R&D, 2018-2023
14.6.3.3 Regional Market Shares, 2023
14.6.3.4 Business Segment Market Shares, 2023
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Astellas Pharma Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2018-2023
14.7.3.2 R&D, 2018-2023
14.7.3.3 Regional Market Shares, 2023
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Daiichi Sankyo Company, Limited
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.8.4 Strategic Outlook
14.9 GSK plc
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2018-2023
14.9.3.2 R&D, 2018-2023
14.9.3.3 Regional Market Shares, 2023
14.9.3.4 Business Segment Market Shares, 2023
14.9.4 Product Benchmarking
14.10 ADC Therapeutics SA
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2018-2023
14.10.3.2 R&D, 2018-2023
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 Synaffix BV (now a part of Lonza)
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Product Benchmarking
14.11.4 Strategic Outlook
14.12 Byondis
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Product Benchmarking
14.13 AbbVie Inc.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2018-2023
14.13.3.2 R&D, 2018-2023
14.13.3.3 Regional Market Shares, 2023
14.13.3.4 Business Segment Market Shares, 2023
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 RemeGen
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Oxford BioTherapeutics
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Product Benchmarking
14.16 Mersana Therapeutics
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Product Benchmarking
14.17 WuXi AppTec
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2018-2023
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
14.18 Genmab A/S
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.3.1 Net Revenue, 2018-2023
14.18.3.2 R&D, 2018-2023
14.18.4 Product Benchmarking
14.18.5 Strategic Outlook
14.19 Regeneron Pharmaceuticals Inc.
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2018-2023
14.19.3.2 R&D, 2018-2023
14.19.3.3 Regional Market Shares, 2023
14.19.3.4 Business Segment Market Shares, 2023
14.19.4 Product Benchmarking

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Antibody Drug Conjugates Market Snapshot, 2025 & 2035 (US$ Billion, CAGR %)
Table 2 Antibody Drug Conjugates Drugs Market: Pipeline
Table 3 Snapshot of Few Antibody Drug Conjugates Investment Deals
Table 4 Antibody Drug Conjugates Drugs Market: Approved ADCs
Table 5 Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 6 MMAE Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 7 DM4 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 8 Camptothecin Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 9 DM1 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 10 MMAF Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 11 Other Payload Type Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 12 Antibody Drug Conjugates Market Forecast by Technology, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 13 Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 14 Non-Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 15 Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 16 CD30 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 17 HER2 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 18 CD22 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 19 CD33 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 20 Other Target Antigens Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 21 Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 22 Blood Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 23 Breast Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 24 Ovarian Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 25 Lung Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 26 Other Applications Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 27 Antibody Drug Conjugates Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 28 North America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 29 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 30 North America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 31 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 32 North America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 33 U.S. Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 34 Canada Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 35 Europe Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 36 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 37 Europe Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 38 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 39 Europe Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 40 Germany Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 41 UK Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 42 France Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 43 Italy Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 44 Spain Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 45 Russia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 46 Rest of Europe Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 47 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 48 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 49 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 50 Asia Pacific Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 51 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 52 Japan Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 53 China Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 54 India Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 55 Australia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 56 South Korea Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 57 South-East Asia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 58 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 59 Latin America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 60 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 61 Latin America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 62 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 63 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 64 Brazil Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 65 Mexico Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 66 Argentina Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 67 Colombia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 68 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 69 MEA Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 70 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 71 MEA Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 72 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 73 MEA Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 74 GCC Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 75 South Africa Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 76 Rest of MEA Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 77 Antibody Drug Conjugates Market, Ranking 2024
Table 78 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 80 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 81 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 83 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 84 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Pfizer Inc.: Product & Services Benchmarking
Table 86 Pfizer Inc.: Strategic Outlook
Table 87 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 AstraZeneca: Product Benchmarking
Table 89 AstraZeneca: Strategic Outlook
Table 90 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Gilead Sciences, Inc.: Product Benchmarking
Table 92 Gilead Sciences, Inc.: Strategic Outlook
Table 93 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Astellas Pharma Inc.: Product Benchmarking
Table 95 Astellas Pharma Inc.: Strategic Outlook
Table 96 Daiichi Sankyo Company, Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Daiichi Sankyo Company, Limited: Product Benchmarking
Table 98 Daiichi Sankyo Company, Limited: Strategic Outlook
Table 99 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 GSK plc: Product Benchmarking
Table 101 ADC Therapeutics SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 ADC Therapeutics SA: Product Benchmarking
Table 103 ADC Therapeutics SA: Strategic Outlook
Table 104 Synaffix BV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Synaffix BV: Product Benchmarking
Table 106 Synaffix BV: Strategic Outlook
Table 107 Byondis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Byondis: Product Benchmarking
Table 109 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 AbbVie Inc.: Product Benchmarking
Table 111 AbbVie Inc.: Strategic Outlook
Table 112 RemeGen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 RemeGen: Product Benchmarking
Table 114 RemeGen: Strategic Outlook
Table 115 Oxford BioTherapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Oxford BioTherapeutics: Product Benchmarking
Table 117 Mersana Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Mersana Therapeutics: Product Benchmarking
Table 119 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 WuXi AppTec: Product Benchmarking
Table 121 WuXi AppTec: Strategic Outlook
Table 122 Genmab A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Genmab A/S: Product Benchmarking
Table 124 Genmab A/S: Strategic Outlook
Table 125 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Regeneron Pharmaceuticals Inc.: Product Benchmarking
 
List of Figures
Figure 1 Antibody Drug Conjugates Market Segmentation
Figure 2 Antibody Drug Conjugates Market by Payload Type: Market Attractiveness Index
Figure 3 Antibody Drug Conjugates Market by Linker Type: Market Attractiveness Index
Figure 4 Antibody Drug Conjugates Market by Target Antigen: Market Attractiveness Index
Figure 5 Antibody Drug Conjugates Market by Applications: Market Attractiveness Index
Figure 6 Antibody Drug Conjugates Market Attractiveness Index by Region
Figure 7 Antibody Drug Conjugates Market: Market Dynamics
Figure 8 Antibody Drug Conjugates Market: Impact Analysis
Figure 9 Antibody Drug Conjugates Market: Generalized Process Flow for ADCs
Figure 10 Antibody Drug Conjugates Market: SWOT Analysis
Figure 11 Antibody Drug Conjugates Market: Porter’s Five Forces Analysis
Figure 12 Antibody Drug Conjugates Market: PEST Analysis
Figure 13 Antibody Drug Conjugates Deals, 2010-2023
Figure 14 Antibody Drug Conjugates Market Attractiveness Index by Payload Type
Figure 15 Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
Figure 16 Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025, 2030, 2035 (%)
Figure 17 MMAE Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 18 MMAE Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 19 DM4 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 20 DM4 Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 21 Camptothecin Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 22 Camptothecin Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 23 DM1 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 24 DM1 Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 25 MMAF Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 26 MMAF Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 27 Other Payload Type Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 28 Other Payload Type Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 29 Antibody Drug Conjugates Market Attractiveness Index by Linker Type
Figure 30 Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
Figure 31 Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025, 2030, 2035 (%)
Figure 32 Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 33 Cleavable Linkers Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 34 Non-Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 35 Non-Cleavable Linkers Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 36 Antibody Drug Conjugates Market Attractiveness Index by Target Antigen
Figure 37 Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
Figure 38 Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025, 2030, 2035 (%)
Figure 39 CD30 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 40 CD30 Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 41 HER2 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 42 HER2 Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 43 CD22 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 44 CD22 Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 45 CD33 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 46 CD33 Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 47 Other Target Antigens Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 48 Other Target Antigens Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 49 Antibody Drug Conjugates Market Attractiveness Index by Applications
Figure 50 Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
Figure 51 Antibody Drug Conjugates Market Share Forecast by Applications, 2025, 2030, 2035 (%)
Figure 52 Blood Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 53 Blood Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 54 Breast Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 55 Breast Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 56 Ovarian Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 57 Ovarian Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 58 Lung Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 59 Lung Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 60 Other Applications Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 61 Other Applications Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 62 Antibody Drug Conjugates Market Forecast by Region 2025, 2030, 2035 (Revenue, CAGR%)
Figure 63 Antibody Drug Conjugates Market Share Forecast by Region 2025, 2030, 2035 (%)
Figure 64 Antibody Drug Conjugates Market by Region, 2025-2035 (US$ Billion)
Figure 65 North America Antibody Drug Conjugates Market Attractiveness Index
Figure 66 North America Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 67 North America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 68 North America Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
Figure 69 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
Figure 70 North America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
Figure 71 North America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
Figure 72 North America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
Figure 73 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
Figure 74 North America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
Figure 75 North America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
Figure 76 North America Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
Figure 77 U.S. Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 78 Canada Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 79 Europe Antibody Drug Conjugates Market Attractiveness Index
Figure 80 Europe Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 81 Europe Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 82 Europe Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
Figure 83 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
Figure 84 Europe Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
Figure 85 Europe Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
Figure 86 Europe Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
Figure 87 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
Figure 88 Europe Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
Figure 89 Europe Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
Figure 90 Europe Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
Figure 91 Germany Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 92 UK Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 93 France Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 94 Italy Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 95 Spain Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 96 Russia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 97 Rest of Europe Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 98 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
Figure 99 Asia Pacific Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 100 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 101 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
Figure 102 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
Figure 103 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
Figure 104 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
Figure 105 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
Figure 106 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
Figure 107 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
Figure 108 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
Figure 109 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
Figure 110 Japan Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 111 China Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 112 India Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 113 Australia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 114 South Korea Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 115 South-East Asia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 116 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 117 Latin America Antibody Drug Conjugates Market Attractiveness Index
Figure 118 Latin America Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 119 Latin America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 120 Latin America Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
Figure 121 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
Figure 122 Latin America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
Figure 123 Latin America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
Figure 124 Latin America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
Figure 125 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
Figure 126 Latin America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
Figure 127 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
Figure 128 Latin America Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
Figure 129 Brazil Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 130 Mexico Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 131 Argentina Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 132 Colombia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 133 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 134 MEA Antibody Drug Conjugates Market Attractiveness Index
Figure 135 MEA Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 136 MEA Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 137 MEA Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
Figure 138 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
Figure 139 MEA Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
Figure 140 MEA Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
Figure 141 MEA Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
Figure 142 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
Figure 143 MEA Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
Figure 144 MEA Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
Figure 145 MEA Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
Figure 146 GCC Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 147 South Africa Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 148 Rest of MEA Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 149 Takeda Pharmaceutical Company Limited: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 150 Takeda Pharmaceutical Company Limited: R&D, 2018-2023 (US$ Million, AGR %)
Figure 151 Takeda Pharmaceutical Company Limited: Regional Market Shares (%), 2023
Figure 152 F. Hoffmann-La Roche Ltd.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 153 F. Hoffmann-La Roche Ltd.: R&D, 2018-2023 (US$ Million, AGR %)
Figure 154 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares (%), 2023
Figure 155 Pfizer Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 156 Pfizer Inc.: R&D, 2018-2023 (US$ Million, AGR %)
Figure 157 Pfizer Inc.: Regional Market Shares (%), 2023
Figure 158 Pfizer Inc.: Business Segment Market Shares (%), 2023
Figure 159 AstraZeneca: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 160 AstraZeneca: R&D, 2018-2023 (US$ Million, AGR %)
Figure 161 AstraZeneca: Regional Market Shares (%), 2023
Figure 162 Gilead Sciences, Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 163 Gilead Sciences, Inc.: R&D, 2018-2023 (US$ Million, AGR %)
Figure 164 Gilead Sciences, Inc.: Regional Market Shares (%), 2023
Figure 165 Gilead Sciences, Inc.: Business Segment Market Shares (%), 2023
Figure 166 Astellas Pharma Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 167 Astellas Pharma Inc.: R&D, 2018-2023 (US$ Million, AGR %)
Figure 168 Astellas Pharma Inc.: Regional Market Shares (%), 2023
Figure 169 GSK plc: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 170 GSK plc: R&D, 2018-2023 (US$ Million, AGR %)
Figure 171 GSK plc: Regional Market Shares (%), 2023
Figure 172 GSK plc: Business Segment Market Shares (%), 2023
Figure 173 ADC Therapeutics SA: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 174 ADC Therapeutics SA: R&D, 2018-2023 (US$ Million, AGR %)
Figure 175 AbbVie Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 176 AbbVie Inc.: R&D, 2018-2023 (US$ Million, AGR %)
Figure 177 AbbVie Inc.: Regional Market Shares (%), 2023
Figure 178 AbbVie Inc.: Business Segment Market Shares (%), 2023
Figure 179 WuXi AppTec: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 180 Genmab A/S: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 181 Genmab A/S: R&D, 2018-2023 (US$ Million, AGR %)
Figure 182 Regeneron Pharmaceuticals Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 183 Regeneron Pharmaceuticals Inc.: R&D, 2018-2023 (US$ Million, AGR %)
Figure 184 Regeneron Pharmaceuticals Inc.: Regional Market Shares (%), 2023
Figure 185 Regeneron Pharmaceuticals Inc.: Business Segment Market Shares (%), 2023